Nuformix plc (LON:NFX – Get Free Report)’s stock price reached a new 52-week low on Monday . The stock traded as low as GBX 0.18 ($0.00) and last traded at GBX 0.21 ($0.00), with a volume of 322484 shares trading hands. The stock had previously closed at GBX 0.19 ($0.00).
Nuformix Stock Performance
The company has a current ratio of 1.51, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The stock has a market capitalization of £1.56 million, a PE ratio of -1.63 and a beta of 0.29. The firm’s fifty day moving average price is GBX 0.23 and its two-hundred day moving average price is GBX 0.28.
Nuformix Company Profile
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- What is the FTSE 100 index?
- ASML Fires Warning Shot For Tech Investors
- ESG Stocks, What Investors Should Know
- Prologis Stock Leading U.S. Logistics Boom
- How to Calculate Options Profits
- Johnson & Johnson’s Q1 Checkup: Mixed Results, Optimism Remains
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
